ASP-4345

ASP-4345
Clinical data
Other namesASP4345
Routes of
administration		Oral[1][2][3]
Drug classDopamine D1 receptor positive allosteric modulator
ATC code
  • None
Pharmacokinetic data
Elimination half-life9.1–26.8 hours[3]
Identifiers
  • 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H14ClF3N4O3
Molar mass438.79 g·mol−1
3D model (JSmol)
  • CN(CC1=NC2=C(N1)C=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O
  • InChI=1S/C19H14ClF3N4O3/c1-26(8-16-24-12-4-2-10(19(21,22)23)6-13(12)25-16)17(28)9-27-14-7-11(20)3-5-15(14)30-18(27)29/h2-7H,8-9H2,1H3,(H,24,25)
  • Key:YJODOMNPYLHYJK-UHFFFAOYSA-N

ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.[1][4][5][3] It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia.[1] The drug is taken orally.[1][2][3]

The most common side effects of ASP-4345 have been found to be headache and somnolence.[2] No changes in mood or suicidality were observed.[2] The pharmacokinetics of ASP-4345 have been studied.[3] The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours.[3] Its mean elimination half-life is 9.1 to 26.8 hours.[3]

ASP-4345 is or was under development by Astellas Pharma.[1][4] As of March 2021, no recent development has been reported.[1] The drug has reached phase 2 clinical trials for schizophrenia.[1][4] It was found to be ineffective in a phase 2 trial.[5]

See also

References

  1. ^ a b c d e f g "ASP 4345". AdisInsight. 9 March 2021. Retrieved 27 May 2026.
  2. ^ a b c d Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, et al. (May 2021). "Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia". Neuropsychopharmacology. 46 (6): 1145–1151. doi:10.1038/s41386-020-00908-0. PMC 8182805. PMID 33203954.
  3. ^ a b c d e f g Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, et al. (January 2021). "Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies". Clinical Pharmacokinetics. 60 (1): 79–88. doi:10.1007/s40262-020-00911-0. PMC 7808976. PMID 32533536.
  4. ^ a b c "Delving into the Latest Updates on ASP-4345 with Synapse". Synapse. 15 November 2025. Retrieved 27 May 2026.
  5. ^ a b Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI (September 2021). "Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments". International Journal of Molecular Sciences. 22 (18): 9905. doi:10.3390/ijms22189905. PMC 8468549. PMID 34576069.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.